BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

Simple Summary Apoptosis, a programmed form of cell death, represents the main
mechanism by which cells die. Such phenomenon is highly regulated by the BCL-2 family of …

Simple Summary The development of BCL-2 inhibitors as a pivotal approach in cancer
treatment lies in their ability to effectively trigger apoptosis in tumor cells. Venetoclax, a …

Abstract Dual Bcl-2/Bcl-xL inhibitors are expected to deliver therapeutic benefit in many
haematological and solid malignancies, however, their use is limited by tolerability issues …

BCL-XL and BCL-2 are key anti-apoptotic proteins and validated cancer targets. 753B is a
novel BCL-XL/BCL-2 proteolysis targeting chimera (PROTAC) that targets both BCL-XL and …

BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins
which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the …

Background Pilocytic astrocytoma (PA) is the most common pediatric brain tumor and a
mitogen-activated protein kinase (MAPK)-driven disease. Oncogenic MAPK-signaling drives …

Simple Summary Venetoclax–azacitidine is a new standard for elderly or unfit acute myeloid
leukemia patients. Nevertheless, resistance remains a matter of concern. The main genetic …

Apoptosis is the major mode of programmed cell death, which conduces to maintain tissue
homeostasis, clearance of abnormal cells and development of organisms. Over the past two …

Abstract The B‐cell lymphoma‐2 (BCL‐2) family of proteins plays a crucial role in the
regulation of apoptosis, offering a dual mechanism for its control. Numerous studies have …